KyungDong Pharm home
Prescription Medicines

Atodipin Tab.

Product Category
Treatment for high blood pressure and hyperlipidemia
Active Ingredients
Atorvastatin calcium and amlodipine besylate
Appearance
A white or pale yellow, oval, film-coated tablet.
Reimbursement Code
648102590
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Atorvastatin calcium (USP) ---------- 10.85mg (10mg as atorvastatin)
Amlodipine besylate (USP) ---------- 6.94mg (5mg as amlodipine)
- Additives: Microcrystalline cellulose, titanium oxide, magnesium stearate, pregelatinized starch, precipitated calcium carbonate, colloidal silicon oxide, croscarmellose sodium,
Polysorbate 80, polyethylene glycol 6000, hydroxypropyl cellulose, hypromellose 2910

2. Efficacy/Effectiveness
This medicine is only used in patients who need to take two drugs (amlodipine (es-amlodipine) and atorvastatin) simultaneously.

♦ Amlodipine (S-Amlodipine)

1. Myocardial ischemia caused by hypertension, fixed occlusion of the coronary artery (stable angina), or vasospasm and vasoconstriction of the coronary vascular system (atypical angina)
2. Patients with coronary heart disease recently confirmed by angiography and who do not have heart failure or cardiac output less than 40%
- Reduces the risk of hospitalization due to angina pectoris
- Reduced risk of coronary artery revascularization

♦ Atorvastatin

1. Reduces the risk of the following cardiovascular diseases:
1) There is no clinical evidence for coronary heart disease, but multiple risk factors for coronary heart disease (age, smoking, high blood pressure, low HDL-cholesterol level, or early coronary heart disease)
Adult patients with a family history, etc.
A. Reduced risk for myocardial infarction
B. Reduced risk for stroke
c. Reduced risk for revascularization and chronic stable angina
2) Patients with type 2 diabetes who have no clinical evidence of coronary heart disease but have multiple risk factors for coronary heart disease (retinopathy, albuminuria, smoking, or high blood pressure, etc.)
A. Reduced risk for myocardial infarction
B. Reduced risk for stroke
3) Adult patients with clinical evidence of coronary heart disease
A. Reduced risk for non-fatal myocardial infarction
B. Reduced risk for fatal and non-fatal stroke
c. Reduced risk of revascularization
D. Reduced risk of hospitalization for congestive heart failure
E. Reduced risk for angina pectoris
2. Elevated total cholesterol in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed (mixed) dyslipidemia (Fredrickson Type IIa and IIb);
Dietary supplement that reduces LDL-cholesterol, apo-B protein, and triglyceride levels and increases HDL-cholesterol levels.
3. Dietary supplement for patients with elevated serum triglycerides (Fredrickson Type IV)
4. Primary dysbetalipoproteinemia (Fredrickson Type III) that does not respond appropriately to diet therapy
5. To reduce total cholesterol and LDL-cholesterol levels in patients with homozygous familial hypercholesterolemia, use in combination with other lipid-lowering drugs (e.g. LDL-apheresis),
When treatment with these lipid-lowering drugs is not possible

3. Usage/Dosage
This drug is administered only to adults, and the dosage should be individualized for each patient based on the effectiveness and tolerability of each component of amlodipine/atorvastatin.

♦ Amlodipine (S-Amlodipine)
- Adults: Amlodipine (es-amlodipine) is administered orally at 5 (2.5) mg once a day, and the dose can be increased up to 10 (5) mg per day depending on the patient's response. Increase or decrease appropriately depending on symptoms.

♦ Atorvastatin
Patients before and while taking atorvastatin must eat a standard cholesterol-lowering diet, and the drug can be administered at any time of the day, regardless of food.

1. Patients with primary hypercholesterolemia (heterozygous familial and non-familial types) and mixed dyslipidemia (Fredrickson Type Ⅱa and Ⅱb)
The recommended initial dose of this drug is 10 mg once daily, but for patients requiring a greater reduction in LDL-cholesterol levels, 20 mg or 40 mg once daily (LDL-cholesterol level of 45% or more)
(limited to cases where cholesterol level reduction is required).
This drug is administered once a day in a dosage range of 10 mg to 80 mg, and can be administered at any time of the day, regardless of food.
The initial dose and maintenance dose of this drug should be individualized according to the patient's characteristics, taking into account treatment goals and responses, and within 2 to 4 weeks after starting administration and/or dose titration.
Lipid levels should be analyzed and dosage adjusted accordingly.

2. Homozygous familial hypercholesterolemia patient
The dosage of this drug is 10 mg to 80 mg once a day, when used in combination with other lipid-lowering treatments (e.g., LDL apheresis) or when such lipid-lowering treatments are not possible.
Administer this medicine.

3. Patients with renal failure
Kidney disease does not affect the plasma concentration or LDL-cholesterol lowering effect of atorvastatin, so there is no need to adjust the dose.

4. Elderly people
Efficacy and safety in elderly people over 70 years of age are similar to those in the general adult patient population.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with or history of hypersensitivity to this drug or other dihydropyridine drugs or components of this drug
2) Patients with severe liver dysfunction, patients with active liver disease, or patients with unexplained elevations in serum transaminase levels that persist more than 3 times the upper limit of normal, patients with bile secretion arrest and myopathy.
3) Pregnant women or women who may be pregnant (administer only when administered to women of childbearing age who are highly likely not to become pregnant and when informed of the potential risk to the fetus) and lactating women.
4) Patients with muscle disease
5) Patients with severe aortic stenosis
6) Shock patients (including cardiogenic shock)
7) Patients with severe low blood pressure
8) Patients within 1 month after myocardial infarction
9) Patients with unstable angina pectoris
10) Patients receiving glecaprevir and pibrentasvir

2. Administer with caution to the following patients.
1) Patients with severe renal dysfunction (including patients with renal failure requiring dialysis)
2) Elderly people
3) Patients who are alcoholics, consume a significant amount of alcohol, or have or have a history of liver disease (see ‘Adverse Reactions’ section)
4) For patients with the following predisposition to rhabdomyolysis, the creatine kinase (CK) level should be measured before starting treatment and administration should be administered with caution.
(1) Patients with a history of impaired renal function or renal dysfunction
(2) Patients with hypothyroidism
(3) Patients with a personal or family history of hereditary muscle abnormalities
(4) Patients with a history of muscle toxicity when using statins or fibrils
(5) If you have a history of liver disease or consume a significant amount of alcohol
(6) Elderly patients over 70 years of age with a predisposition to rhabdomyolysis
5) Patients with acute heart failure
6) Patients with hypertensive crisis
7) Patients with mild to moderate liver dysfunction
8) Patients with severe muscle atony or ocular muscle atony (cases of recurrence when administered the same or different types of statin drugs have been reported).

3. Adverse reactions
As a result of conducting a double-blind, placebo-controlled study to evaluate the safety of this drug (amlodipine/atorvastatin combination) in 1,092 patients with both high blood pressure and hyperlipidemia, no adverse reactions specific to this drug were observed. Adverse events were similar to those previously reported with amlodipine and atorvastatin.
In general, the drug was well tolerated. In most cases, adverse reactions were mild or moderate. In controlled clinical trials, discontinuation of the trial due to adverse reactions or laboratory abnormalities was 4.0% in the placebo group and 5.1% in the amlodipine/atorvastatin combination treatment group. The information specified below is based on clinical trials and post-marketing experience with the individual ingredients amlodipine and atorvastatin.

Information Collected from Amlodipine
1) Amlodipine is well tolerated. In placebo-controlled clinical trials on patients with hypertension and angina pectoris, the most common adverse reactions were as follows.
(1) Vascular system: flushing
(2) Whole body: fatigue, swelling
(3) Cardiovascular system: palpitations
(4) Nervous system: dizziness, headache, drowsiness
(5) Digestive system: abdominal pain, nausea
No clinically significant laboratory abnormalities related to this drug were observed in clinical trials.
2) Adverse reactions observed with relatively low frequency after the marketing of amlodipine are as follows.
(1) Whole body: weakness, malaise, pain, increase/decrease in weight
(2) Vascular system: hypotension, vasculitis
(3) Nervous system: hypertonia, hypoesthesia/paresthesia, peripheral neuropathy, syncope, abnormal taste, tremor, extrapyramidal disorder
(4) Reproductive system: erectile dysfunction, gynecomastia
(5) Digestive system: Changes in bowel habits, dry mouth, indigestion (gastritis), gingival thickening, gum hyperplasia, pancreatitis, vomiting
(6) Metabolism/Nutrition: Hyperglycemia
(7) Musculoskeletal system: joint pain, back pain, muscle cramps, muscle pain
(8) Blood and lymphatic system: leukopenia, thrombocytopenia
(9) Mental system: insomnia, mood changes
(10) Respiratory system: cough, difficulty breathing, rhinitis
(11) Skin/accessory systems: hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis
(12) Sensory system: sound in ears, visual impairment
(13) Urinary system: increased urination frequency, urination disorder, enuresis
(14) Liver/biliary system: Hepatitis, jaundice, and elevated liver enzyme levels were reported very rarely, and most of these were related to cholestasis. Some cases that were severe enough to require hospitalization were reported to be related to the use of amlodipine, but in most cases, the causal relationship with amlodipine is unclear.
(15) Rarely, allergic reactions including itching, rash, angioedema, and erythema multiforme have been reported.
3) As with other calcium channel blockers, the following adverse reactions were rarely reported, but it was not possible to distinguish whether they were caused by the underlying disease or the drug. : Myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia, atrial fibrillation), chest pain
4) Other adverse reactions as follows were observed.
(1) Cardiovascular system: Occasionally, a drop in blood pressure, sinoatrial or atrioventricular block, and rarely abdominal discomfort may occur.
(2) Digestive system: Occasionally, abdominal pain, diarrhea, loose stools, constipation, etc. may occur.
(3) Skin: In rare cases, redness of the skin, spotting, and papular rash may appear.
(4) Others: Occasionally, heaviness, hot flashes, decreased glucose tolerance, and weakness may occur.

Information collected from Atorvastatin
1) Atorvastatin is generally well tolerated. Adverse reactions were generally mild and transient. Treatment discontinuation during clinical trials due to adverse reactions related to this drug occurred in less than 2% of patients. In a placebo-controlled clinical trial for atorvastatin, 16,066 patients (8,755 in the atorvastatin group vs. 7,311 in the placebo group) received the drug for a median period of 53 weeks, and 4.0% of the placebo group and 5.2% of the atorvastatin group discontinued treatment due to adverse reactions.
2) Among patients who participated in placebo-controlled clinical studies, the most common adverse reactions (more than 1%) related to atorvastatin are as follows. Not all adverse reactions described below are causally related to atorvastatin.
(1) Whole body: helplessness
(2) Infection: Nasopharyngitis
(3) Metabolic system: hyperglycemia
(4) Digestive system: indigestion, nausea, abdominal distension (flatulence), constipation, diarrhea, abdominal pain
(5) Respiratory system: pain in the larynx, nosebleeds
(6) Mental/nervous system: headache, insomnia
(7) Musculoskeletal system and connective tissue: muscle pain, joint pain, limb pain, musculoskeletal pain, muscle spasm, joint swelling
(8) Test: Abnormal liver function test, increased CK in blood
3) During the atorvastatin placebo-controlled clinical study, the following additional adverse reactions occurred. Not all adverse reactions described below are causally related to atorvastatin.
(1) Psychological nervous system: nightmare
(2) Eye abnormality: blurred vision
(3) Ear and labyrinth: tinnitus
(4) Digestive system: Vomiting, abdominal discomfort, hepatitis, pancreatitis, cholestasis, cholestatic jaundice, abnormal liver function test values (elevated serum ALT level), gastroenteritis, enteritis, dry mouth, rectal bleeding, esophagitis, burping, glossitis, oral ulcer, stomatitis, gallbladder pain, cheilitis, stomach and duodenal ulcer, dysphagia, melena, gingival bleeding, secondary weight (remaining after excretion) pain)
(5) Respiratory system: bronchitis, rhinitis, pneumonia, difficulty breathing. Asthma, epistaxis
(6) Nervous system: sensory abnormalities (paresthesia), peripheral neuropathy, dizziness, sensitivity to light, drowsiness, forgetfulness, abnormal dreams, decreased libido, emotional anxiety, motor incoordination, torticollis, facial paralysis, hyperkinesia, depression, hypertonia.
(7) Musculoskeletal system and connective tissue: muscle cramps, muscle fatigue, myositis, muscle disease, arthritis, bursitis, tenosynovitis, myasthenia gravis, neck pain, tendon contracture, increased CK, increased blood myoglobin.
(8) Skin and subcutaneous tissue: itching, rash, alopecia, contact dermatitis, dry skin, sweating, acne, urticaria, eczema, seborrhea, skin ulcers
(9) Urogenital system: impotence, urinary tract infection, frequent urination, cystitis, hematuria, dysuria, kidney stones, nocturia, epididymitis, breast fibroid cyst, vaginal bleeding, albuminuria, breast hypertrophy, cervical discharge, nephritis, urinary incontinence, urinary retention, urgency, abnormal ejaculation, uterine bleeding, pigmented urine.
(10) Metabolic and nutritional disorders: hypoglycemia, hyperglycemia, anorexia, increased appetite
(11) Systemic abnormalities and administration site abnormalities: malaise, angioedema, chest pain, angina, facial edema, fever, neck stiffness, whole body edema
(12) Special senses: amblyopia, tinnitus, dry eyes, refractive error, eye hemorrhage, hearing loss, glaucoma, parosmia, loss of taste, perversion of taste.
(13) Blood and lymphatic system: thrombocytopenia, leukopenia, anemia
(14) Endocrine: decreased testosterone, increased cholinesterase, increased TSH, increased ACTH, decreased aldosterone, gynecomastia.
(15) Kidney: Increased potassium, increased BUN
(16) Others: cerebral infarction, palpitations, tachycardia
(17) Test: positive white blood cells in urine
4) The following adverse reactions not specified above have been reported after marketing.
(1) Abnormalities in the entire body and administration site: chest pain, malaise, fatigue
(2) Vascular system: vasculitis
(3) Musculoskeletal system: arthralgia, rhabdomyolysis, back pain, tendon rupture, immune-mediated necrotizing myopathy, back pain, myositis
(4) Nervous system: decreased sensation, abnormal sense of taste, amnesia, dizziness
(5) Digestive system: pancreatitis
(6) Skin and subcutaneous tissue: blistering rash, erythema multiforme, toxic epidermal necrolysis, mucocutaneous ocular syndrome (Stevens-Johnson syndrome), angioedema, lichenoid drug reaction
(7) Metabolic and nutritional disorders: peripheral edema, weight gain
(8) Immune system: allergic reaction (anaphylaxis)
5) In clinical studies, an increase in plasma CK levels (more than 3 times the normal range) occurred in 3.1% of cases with other HMG-CoA reductase inhibitors, compared to 2.5% with atorvastatin. Cases showing levels more than 10 times the upper limit of normal range occurred in 0.4% of patients receiving atorvastatin. Of these patients, 0.1% had muscle pain, sensitivity, or weakness.
6) Effects on the liver: After administration of this drug, adverse reactions such as abnormal liver function, jaundice, fulminant hepatitis, and hepatitis may occur. Therefore, if abnormalities are recognized through sufficient observation such as conducting regular tests, discontinue administration and take appropriate measures. As with other HMG-CoA reductase inhibitors, increases in serum transaminases (>3 times the upper limit of normal) have been reported in patients receiving atorvastatin. This increase was dose proportional and reversible. Liver function tests should be performed before starting treatment, and liver function tests should be performed periodically thereafter. For patients showing symptoms of liver damage, liver function tests should be performed. Patients with increased transaminase levels should be monitored until these abnormal levels resolve. In pre-marketing and post-marketing clinical trials, liver function was monitored after administration of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin. Continuous increases in serum transaminase levels (more than 3 times the upper limit of normal value (ULN) more than twice) occurred in 0.7% of patients treated with atorvastatin (0.2% in the 10 mg group, 0.2% in the 20 mg group, 0.6% in the 40 mg group, and 2.3% in the 80 mg group). Increased serum transaminase levels are generally not associated with jaundice or other clinical signs or symptoms. When the dose of atorvastatin was reduced, temporarily discontinued, or discontinued, the transaminase level returned to the pre-administration level. Most patients continued treatment with reduced doses of atorvastatin without sequelae. If transaminase levels, ALT, or AST increase more than three times the upper limit of normal, the dose of atorvastatin should be reduced or discontinued. Atorvastatin should be administered cautiously to alcohol abusers (overdosers) or people with a history of liver disease. Atorvastatin should not be administered to patients with active liver disease or patients with persistent unexplained elevations in serum transaminase levels.
7) Effects on the musculoskeletal system: Muscle pain and simple muscle disorders have been reported in patients administered atorvastatin. In all patients with elevated CK levels, it should be considered whether muscle disease (defined as an increase in CK more than 10 times the upper limit of normal and the appearance of diffuse muscle pain, muscle tension, muscle weakness, etc.) occurs. Patients should be instructed to immediately report unexplained muscle pain, muscle tension, or muscle weakness (especially if accompanied by lethargy or fever). Atorvastatin administration should be discontinued if CK levels rise significantly or muscle disease is diagnosed or suspected.
Immune-mediated necrotizing myopathy, an autoimmune myopathy associated with statin use, has been rarely reported. Immune-mediated necrotizing myopathy occurs with proximal muscle weakness and increased CK in the blood, and the symptoms persist even after discontinuation of statin administration. Additionally, muscle biopsy shows necrotizing myopathy without significant infection, and symptoms improve when immunosuppressants are administered.
Most of these drugs inhibit CYP-450 3A4 metabolism and/or drug transport. Atorvastatin is converted in vivo by CYP-450 3A4. Macrolide antibiotics and azole antifungals should be administered cautiously in combination with this drug. The risk of myopathy during drug therapy in this class is increased with cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, elbasvir, grazoprevir, telaprevir, boceprevir, HIV protease inhibitor combination therapy (saquinavir/ritonavir combination, lopinavir/ritonavir combination, tipranavir/ritonavir combination, It increases when administered in combination with darunavir/ritonavir combination, fosamprenavir, fosamprenavir/ritonavir combination), nicotinic acid, azole antifungal agents, and colchicine. Physicians considering co-administration of fibric acid derivatives or lipid-altering doses of nicotinic acid and atorvastatin should carefully consider whether the therapeutic benefits outweigh the risks, and carefully monitor signs and symptoms related to muscle pain, muscle tension, or muscle weakness (particularly in the first month of administration and the appropriate period for increasing the dose of either drug). Therefore, when coadministering atorvastatin with the drugs described above, a reduction in the starting and maintenance doses of atorvastatin should be considered. Atorvastatin and fusidic acid (oral medication) should not be administered together. Periodic measurement of CK levels should be considered, but there is no certainty that monitoring will prevent the development of serious myopathy. This drug can increase CK due to the atorvastatin component. As with other drugs in this class, renal dysfunction secondary to myoglobinuria has rarely been shown to cause rhabdomyolysis. A history of renal dysfunction may be a risk factor for developing rhabdomyolysis. These patients may benefit from close monitoring of musculoskeletal effects. In patients with acute and serious myopathy or risk factors predisposing to the development of renal insufficiency secondary to myoglobinuria (severe acute hepatitis, hypotension, mainly surgical procedures, trauma, severe metabolic disorders, endocrine and electrolyte disorders, uncontrolled seizures), treatment with this drug should be temporarily withheld or discontinued.
8) Hemorrhagic stroke: In one post-hoc analysis of a clinical trial in which 80 mg of atorvastatin was administered as a starting dose to 4,731 patients who had no history of coronary heart disease but had experienced a stroke or transient ischemic attack within the past 6 months, it was reported that the occurrence of hemorrhagic stroke was higher in the atorvastatin 80 mg group compared to the placebo group (atorvastatin group) 55 people vs. 33 placebo group). This risk appears to have increased in patients who had already had a hemorrhagic stroke at the start of the clinical trial (7 patients in the atorvastatin group vs. 2 in the placebo group). However, in patients receiving 80 mg of atorvastatin, the overall incidence of stroke (265 patients in the atorvastatin group vs. 311 in the placebo group) and the incidence of coronary heart disease (123 in the atorvastatin group vs. 204 in the placebo group) were lower than those in the placebo group.
9) Endocrine function: An increase in HbA1c and fasting serum blood sugar levels was observed when concurrently administering HMG-CoA inhibitors, including atorvastatin. However, the benefit of reducing vascular risk due to administration of statins outweighs the risk of hyperglycemia.
10) The results of the usage results survey conducted in Korea for 6 years after marketing are as follows.
(1) General use results survey: As a result of a post-marketing survey conducted on 11,535 people, the frequency of adverse reactions was reported to be 1.78% (205 cases/11,535 cases) regardless of causal relationship. Among these, new adverse reactions that did not appear in pre-marketing clinical trials were reported as hypertriglyceridemia in 7 cases, facial flushing in 4 cases, non-proteinaceous increase in 3 cases, hyperuricemia in 3 cases each, and gingival thickening in 1 case.
(2) Long-term use results survey: As a result of a long-term post-marketing survey conducted on 2,625 people who took this drug for more than 12 weeks, the frequency of adverse reactions was reported to be 3.70% (97 cases/2,625 cases) regardless of causal relationship. Among these, seven cases of hyperuricemia, facial flushing, hypothermia, and increase in non-protein content were reported as new adverse reactions that did not appear in pre-market clinical trials.
11) The following adverse reactions have been reported in relation to some statin drugs.
(1) Mental nervous system: sleep disorders (including insomnia and nightmares), memory loss, depression
(2) Respiratory system: exceptional cases such as interstitial lung disease, especially during long-term administration
(3) Urogenital system: sexual dysfunction
(4) Endocrine system: Diabetes: The frequency varies depending on the presence of risk factors. (Fasting blood sugar 5.6~6.9 mmol/L, BMI>30kg/m2, increased triglyceride level, high blood pressure)
(5) Post-marketing cognitive impairment has been rarely reported in association with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks).
(6) The induction or worsening of severe muscle atony or ocular muscle atony has been reported in connection with the administration of statin drugs.

4. General precautions
Based on the available information about amlodipine and atorvastatin, it appears that amlodipine does not impair the ability to drive or use machines.

Amlodipine
1) Administration to heart failure patients: In a long-term, placebo-controlled trial (PRAISE-2) of amlodipine in New York Heart Association (NYHA) class III and IV heart failure patients without ischemic etiology, amlodipine was associated with an increase in reports of pulmonary edema despite no significant difference in the worsening rate of heart failure compared to placebo.
2) Administration to patients with liver dysfunction: Like all calcium channel blockers, the half-life of amlodipine is prolonged in patients with liver dysfunction, and the recommended dosage for these patients has not been established. Therefore, administer with caution to these patients.
3) Because the plasma concentration half-life is long, a gradual blood pressure lowering effect appears even after discontinuation of administration. Therefore, when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
4) Since the effect appears slowly, the effect cannot be expected for unstable angina pectoris that requires emergency treatment.
Atorvastatin
1) Gender: The concentration of atorvastatin in women (Cmax is approximately 20% higher and AUC is approximately 10% lower) is different from that in men. These differences were not clinically significant, and the effects on lipids were not clinically different between men and women.
2) Renal failure: Renal disease did not affect the plasma concentration or LDL-cholesterol lowering effect of atorvastatin.
3) Liver failure: The plasma concentration of atorvastatin increased significantly (Cmax about 16 times, AUC about 11 times) in patients with chronic alcoholic liver disease (Childs-Pugh Class B). Rare post-marketing cases of fatal and non-fatal liver failure have been reported in patients taking statins, including this drug. If severe liver damage and/or hyperbilirubinemia or jaundice with clinical symptoms occurs while taking this drug, treatment should be discontinued immediately. Do not re-administer this drug if no other etiology is found.
4) Hepatitis: Hepatitis such as fulminant hepatitis may occur after taking this drug. If symptoms such as nausea, vomiting, or malaise occur, stop taking the drug and notify your doctor.
5) Women of childbearing potential: Women of childbearing potential receiving this drug must use appropriate contraception while taking this drug.
6) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, non-productive coughing and general deterioration of health (fatigue, weight loss and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
7) Co-administration with other drugs: When atorvastatin is co-administered with cyclosporine, the administered dose of atorvastatin should not exceed 10 mg.
8) Diabetes: Some evidence has been presented that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines.
9) In rare cases, statin drugs may cause or worsen severe muscle atony or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.
10) Myopathy and/or rhabdomyolysis have been reported when daptomycin and HMG-CoA reductase inhibitors were administered together. Daptomycin and HMG-CoA reductase inhibitors may cause myopathy and/or rhabdomyolysis when administered alone, so caution should be exercised when coadministered. In patients receiving daptomycin, temporary discontinuation of daptomycin should be considered.

5. Interaction
The results of a drug-drug interaction test conducted by administering 10 mg of amlodipine and 80 mg of atorvastatin to healthy volunteers showed that the pharmacokinetics of amlodipine were not affected when these two drugs were co-administered. In the presence of amlodipine, the Cmax of atorvastatin was not affected (Cmax: 91%: 90% confidence interval, 80-103%), but the AUC increased by about 18% (AUC: 1.18, 90% confidence interval, 109-127%). There are no studies on drug interactions between other drugs and the amlodipine/atorvastatin combination, but studies on the individual drugs amlodipine and atorvastatin were conducted as follows.

Amlodipine
1) Amlodipine is safe when used in combination with thiazide diuretics, alpha-blockers, beta-blockers, ACE inhibitors, long-acting nitrate preparations, nitroglycerin sublingual tablets, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and oral hypoglycemic agents.
2) Laboratory data using human plasma show that amlodipine does not affect the protein binding of digoxin, phenytoin, warfarin, and indomethacin.
3) Grapefruit juice: A single co-administration of 240 mL of grapefruit juice and 10 mg of amlodipine in 20 healthy volunteers did not significantly affect the pharmacokinetics of amlodipine. In this trial, the impact of genetic polymorphisms in CYP3A4, the main metabolic pathway for amlodipine, was not evaluated. Therefore, co-administration of amlodipine with grapefruit or grapefruit juice is not recommended as the blood pressure lowering effect may increase in some patients due to increased bioavailability.
4) Dantrolene (injection): In animal experiments where verapamil and dantrolene were administered through IV, fatal ventricular spasm was consistently observed. Simultaneous administration of amlodipine and dantrolene should be avoided.
5) Baclofen: As it increases the blood pressure lowering effect, administer with caution regarding blood pressure and dosage if necessary.
6) Clarithromycin: Clarithromycin is a CYP3A4 inhibitor. The risk of hypotension is increased when clarithromycin is coadministered with this drug. It is recommended that patients be carefully observed when coadministering this drug and clarithromycin.
7) How other drugs affect amlodipine
(1) Cimetidine: When administered in combination with amlodipine, there was no effect on the pharmacokinetics of amlodipine.
(2) Aluminum/magnesium (antacid): When administered in combination with aluminum/magnesium antacid and a single dose of amlodipine, there was no significant effect on the pharmacokinetics of amlodipine.
(3) Sildenafil: Administration of a single dose of 100 mg of sildenafil to patients with primary hypertension did not affect the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil are administered together, each drug independently exerts its own blood pressure lowering effect.
(4) CYP 3A4 inhibitor: In elderly (69 to 87 years old) hypertensive patients, coadministration of 180 mg of diltiazem and 5 mg of amlodipine per day increased the systemic exposure of amlodipine by 57%. In healthy volunteers (18 to 43 years of age), coadministration of erythromycin did not significantly change systemic exposure to amlodipine (22% increase in AUC). Although the clinical relevance of this has not been revealed, pharmacokinetic changes may be more evident in elderly people. The possibility that strong CYP 3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase plasma concentrations of amlodipine to levels higher than those seen with co-administration with diltiazem cannot be excluded. Amlodipine should be administered with caution when coadministered with CYP 3A4 inhibitors. However, no adverse reactions resulting from this drug interaction have been reported.
(5) CYP3A4 inducers: Co-administration with CYP3A4 inducers (e.g., rifampicin, St. John's wort (hypericum perforatum), carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
8) Effect of amlodipine on other drugs
(1) Atorvastatin: There was no significant change in the steady-state pharmacokinetic parameters of atorvastatin when administered in combination with 80 mg of atorvastatin and 10 mg of amlodipine repeatedly.
(2) Digoxin: When amlodipine and digoxin were co-administered to normal volunteers, there was no change in serum digoxin levels or digoxin renal clearance.
(3) Alcohol: There was no significant change in the pharmacokinetics of alcohol during single or repeated administration of 10 mg amlodipine.
(4) Warfarin: When amlodipine and warfarin were administered together, there was no effect on the warfarin-prothrombin reaction time.
(5) Cyclosporine: In several studies in which cyclosporine and this drug were co-administered in kidney transplant patients, it was reported that the trough blood concentration of cyclosporine remained unchanged or increased by up to 40% when administered in combination with this drug.
(6) Tacrolimus: When co-administered with this drug, there is a risk of increasing the blood concentration of tacrolimus. Therefore, when administering this drug to patients being treated with tacrolimus, the blood concentration of tacrolimus should be monitored and the dosage of tacrolimus should be appropriately adjusted to avoid tacrolimus toxicity.
(7) mTOR inhibitors: mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus) are substrates of CYP3A. Amlodipine is a weak CYP3A inhibitor, and when administered concomitantly with mTOR inhibitors, amlodipine may increase exposure to mTOR inhibitors.
(8) Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased the exposure of simvastatin by 77% compared to administration of simvastatin alone. In patients receiving amlodipine, the maximum daily dose of simvastatin is up to 20 mg.


Atorvastatin
1) During treatment with other HMG-CoA reductase inhibitors, the risk of muscle disease increased when administered concurrently with immunosuppressants (e.g., cyclosporine), fibric acid derivatives (e.g., gemfibrozil), erythromycin, azole antifungal agents, or lipid-altering doses of nicotinic acid. Many drugs of this class inhibit CYP-450 3A4 metabolism and/or drug transport. Atorvastatin is metabolized by CYP-450 3A4.
2) Since this drug is a substrate of P-glycoprotein, co-administration with a P-glycoprotein inhibitor (e.g. cyclosporine) increases the bioavailability of this drug, increasing the risk of adverse reactions such as muscle disease.
3) When this drug is administered with CYP-450 3A4 inhibitors (cyclosporine, macrolide antibiotics, azole antifungals, and HIV protease), the blood concentration of this drug may increase, so it should be administered with caution. The effect of CYP-450 3A4 inducers (e.g., rifampicin or phenytoin) on atorvastatin is not known.
4) Co-administration of this drug with CYP-450 3A4 inducers (e.g. efavirenz, rifampicin) may decrease the blood concentration of atorvastatin. Because of the dual interaction mechanism of rifampicin (CYP-450 3A4 induction and hepatocyte uptake transporter OATP1B1 inhibition), when atorvastatin and rifampicin are administered together, simultaneous administration is recommended. If atorvastatin is administered late after rifampicin administration, the blood concentration of atorvastatin significantly decreases.
5) No clinically significant interactions were observed in clinical studies using this drug in combination with antihypertensive agents, hypoglycemic agents, or estrogen replacement therapy. Interactions with all unusual agents have not yet been studied.
6) Drug transporter inhibitor: Atorvastatin and its metabolites are substrates of the OATP1B1 transporter. OATP1B1 inhibitors (e.g., cyclosporine) may increase the bioavailability of atorvastatin. Co-administration of atorvastatin 10 mg with cyclosporine 5.2 mg/kg/day increased atorvastatin exposure (AUC ratio: 8.7). When atorvastatin is administered in combination with cyclosporine, the administered dose of atorvastatin should not exceed 10 mg.
7) Breast cancer resistance protein (BCRP) inhibitor: When co-administered with BCRP inhibitors (e.g., elbasvir, grazoprevir), the plasma concentration of atorvastatin may increase, which may increase the risk of myopathy, so dose adjustment of atorvastatin may be necessary. When atorvastatin is administered in combination with elbasvir and grazoprevir, the plasma concentration of atorvastatin increases by 1.9-fold. Therefore, for patients receiving elbasvir or grazoprevir-containing preparations together with this drug, the dose of atorvastatin should not exceed 20 mg per day (see ‘Adverse Reactions’ section).
8) Digoxin: When atorvastatin 10 mg and digoxin are administered in multiple doses, the steady-state plasma concentration of digoxin is not affected. However, after co-administration of 80 mg atorvastatin with digoxin in multiple doses, the steady-state plasma AUC of digoxin increased (AUC ratio: 1.15). Patients receiving digoxin should be appropriately monitored.
9) Erythromycin, clarithromycin: In healthy subjects, atorvastatin plasma concentration increased when atorvastatin was coadministered with erythromycin (500 mg once daily) or clarithromycin (500 mg twice daily), known CYP 450 3A4 inhibitors. Therefore, caution should be exercised when administering more than 20 mg of this drug to patients taking clarithromycin.
10) Oral contraceptives: When this drug was co-administered with oral contraceptives containing noretheristerone and ethinyl estradiol, the AUC of noretheristerone and ethinyl estradiol increased (AUC ratio: 1.28 and AUC ratio: 1.19, respectively). Therefore, women receiving atorvastatin should take this into consideration when choosing an oral contraceptive.
11) Colestipol: When coadministered with colestipol, the plasma concentration of atorvastatin decreased (concentration ratio: 0.74). However, the LDL-cholesterol lowering effect was greater when atorvastatin and colestipol were administered together than when these drugs were administered alone.
12) Antacid: When this drug was co-administered with an oral antacid suspension containing magnesium and aluminum hydroxide, the AUC of atorvastatin decreased.
(AUC ratio: 0.66). However, there was no effect on the reduction of LDL-cholesterol.
13) Warfarin: When administered in combination with warfarin, the effect of oral anticoagulants and the risk of bleeding increased. INR should be monitored more frequently to determine whether to adjust the dose of oral anticoagulants.
14) Cimetidine: No interaction was confirmed in the interaction study between cimetidine and this drug.
15) Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with drugs metabolized via the same CYP-450 isoenzyme are not expected.
16) Azithromycin: Co-administration of atorvastatin (10 mg once daily) and azithromycin (500 mg once daily) did not affect the plasma concentration of atorvastatin.
17) Amlodipine: In a drug-drug interaction test on healthy volunteers, the AUC of atorvastatin increased when 80 mg of atorvastatin and 10 mg of amlodipine were co-administered (AUC ratio: 1.18), but the result was not clinically meaningful.
18) Terfenadine: When atorvastatin and terfenadine were administered together, there was no clinically significant effect on the pharmacokinetics of terfenadine.
19) Protease inhibitors: Co-administration of atorvastatin with protease inhibitors known to inhibit CYP 450 3A4 (e.g., lopinavir, nelfinavir, ritonavir, saquinavir) has been shown to be associated with a 2-5-fold increase in the plasma concentration of atorvastatin. Atorvastatin AUC was significantly increased by co-administration of this drug with several HIV protease inhibitors, as well as the hepatitis C protease inhibitor telaprevir, compared to administration of this drug alone. Therefore, the concomitant use of this drug should be avoided in patients receiving the HIV protease inhibitor tipranovir and ritonavir combination therapy or the hepatitis C protease inhibitor telaprevir. Caution should be exercised when prescribing this drug to patients receiving the HIV protease inhibitor lopinavir and ritonavir combination therapy and the lowest dose should be used. HIV protease inhibitor Saquinavi
In patients receiving darunavir and ritonavir combination therapy, darunavir and ritonavir combination therapy, fosamprenavir, or fosamprenavir and ritonavir combination therapy, the dose of this drug should not exceed 20 mg and should be used with caution. In HIV patients receiving nelfinavir, treatment with nelfinavir is limited to 40 mg, and appropriate clinical evaluation is recommended to ensure that the minimum required dose of nelfinavir is applied. When boceprevir 800 mg, 3 times a day, was administered for 7 days, and 40 mg of boceprevir, once daily, was co-administered on the 7th day, the AUC and Cmax of this drug increased (AUC ratio 2.3, Cmax ratio 2.7). Patients receiving boceprevir should not exceed 40 mg per day.
20) Diltiazem: When atorvastatin (40 mg) and diltiazem (240 mg) were administered together, the blood concentration of atorvastatin was found to be higher.
21) Itraconazole: Co-administration with atorvastatin (20-40 mg) and itraconazole (200 mg) was associated with an increase in the AUC of atorvastatin. Therefore, caution should be exercised when administering more than 20 mg of this drug to patients receiving itraconazole.
22) Grapefruit juice: Grapefruit juice contains ingredients that inhibit one or more CYP 3A4, which can increase the blood concentration of atorvastatin if grapefruit juice is consumed excessively (more than 1L per day). The effect of a certain amount of grapefruit juice (1 250 mL glass per day) on atorvastatin is minimal (13% increased AUC inhibition of HMG-CoA reductase) and clinically irrelevant.
23) Fusidic acid (oral): Although no tests have been conducted on drug interactions between atorvastatin and fusidic acid, severe muscle abnormalities such as rhabdomyolysis have been reported in post-marketing experience with co-administration of these two drugs. These patients should be closely monitored, and atorvastatin treatment should be temporarily discontinued.
24) Colchicine: Although tests on drug interactions between atorvastatin and colchicine have not been conducted, myopathy has been reported in the co-administration of atorvastatin and colchicine. Therefore, caution should be exercised when co-administering atorvastatin and colchicine.
25) Others: In clinical trials, atorvastatin was coadministered with antihypertensive drugs and estrogen replacement therapy drugs without clinically significant interactions. Studies on drug interactions with specific drugs have not been conducted.
26) Gemfibrozil: When gemfibrozil and HMG-CoA reductase inhibitors are administered together, the risk of myopathy/rhabdomyolysis increases, so concurrent administration should be avoided.
27) Other fibrate-based drugs: The risk of myopathy increased when HMG-CoA reductase inhibitors and other fibrate drugs were taken simultaneously.
28) Daptomycin: Combined administration of daptomycin and HMG-CoA reductase inhibitor may cause ???myopathy and/or rhabdomyolysis.
The risk may be????increased.
29) Nicotinic acid: When nicotinic acid and atorvastatin are administered together, the risk of skeletal muscle effects may increase, so a reduction in the atorvastatin dose should be considered.
30) The effect of concomitant drugs on the pharmacokinetics of atorvastatin and the effect of atorvastatin on the pharmacokinetics of concomitant drugs are summarized in the table below.
(Refer to attached document table)

6. Administration to pregnant and lactating women
1) Due to the atorvastatin component of this drug, it is prohibited to be used by pregnant women or women who may be pregnant. Women who have the potential to become pregnant must use appropriate contraception. Cholesterol and its derivatives are so important for embryonic growth that the potential risks of HMG-CoA reductase inhibition outweigh the expected benefits of statin treatment during pregnancy. This drug is administered to women of childbearing age only when there is no possibility of becoming pregnant and after informing them of the potential risk to the fetus. If pregnancy is discovered during treatment, treatment must be stopped immediately and the risk to the fetus must be informed.
2) Due to the atorvastatin component of this drug, it is prohibited to be used by nursing mothers. It is not known whether this drug passes into breast milk, but because of the potential risk of adverse reactions in breast-feeding infants, women taking this drug should not breast-feed.
3) The safety of amlodipine for pregnant and lactating women has not been established. Other than delayed and prolonged parturition in rats administered amlodipine at a dose equivalent to 50 times the recommended maximum dose for humans, no reproductive toxicity has been proven in animals. Therefore, administration to pregnant women is recommended only when there are no other safe alternative drugs and when the disease itself poses a significant risk to the mother and fetus. In human administration experience, it has been reported that amlodipine passes into human breast milk. It is recommended to discontinue breast-feeding while taking this medicine. There was no effect on fertility in rats administered this drug.

7. Administration to children
The safety and effectiveness of this drug in children have not been established.

8. Administration to elderly people
The safety and effectiveness of this drug in elderly people have not been established. Information on the individual drugs amlodipine and atorvastatin is as follows.
1) Amlodipine: It is recommended to administer the usual dose. When amlodipine is administered at similar doses to elderly and young patients, the tolerability is equally good.
2) Atorvastatin: In healthy elderly people over 65 years old, the plasma concentration of atorvastatin was higher than that in the young adult group (40% increase in Cmax, 30% increase in AUC), but the LDL-cholesterol lowering effect was similar to that in the young adult group.

9. Treatment in case of overdose
There is no data on overdose of this drug in humans. Because of the extensive plasma protein binding of amlodipine and atorvastatin, hemodialysis does not appear to significantly benefit the clearance of amlodipine/atorvastatin.
(1) Amlodipine: Current data has shown that severe overdose may result in excessive peripheral vasodilation and reflex tachycardia. In addition, it has been reported that symptoms of systemic hypotension are severe and persist for a long time, leading to a state of shock or resulting in fatal shock. When activated charcoal was administered to healthy volunteers immediately or up to 2 hours after administering 10 mg of amlodipine, the absorption of amlodipine was significantly reduced. In some cases, gastric lavage may be useful.
Clinically serious hypotension caused by overdose of this drug requires active supportive therapy for the cardiovascular system, such as frequent monitoring of heart and respiratory function, maintaining the position of the extremities higher than the body, and ensuring sufficient circulating fluids such as blood and urine excretion. Unless there are special cases where the use of vasoconstrictors is contraindicated, vasoconstrictors may be useful in restoring vascular tone and blood pressure.
Intravenous administration of calcium gluconate may be useful in reversing the effects of calcium channel inhibitors. Because amlodipine has a very high protein binding rate, hemodialysis is not helpful. Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors.
2) Atorvastatin: There is no special treatment method applicable to atorvastatin overdose. In case of overdose, patients must be treated symptomatically and symptomatic treatment administered if necessary. Liver function tests and serum creatine kinase levels should be monitored. Because atorvastatin is extensively bound to plasma proteins, hemodialysis does not significantly increase the clearance of atorvastatin.

10. Other
preclinical data
No studies have been conducted on fixed combinations of amlodipine and atorvastatin.
1) Carcinogenicity
(1) Amlodipine: No evidence of carcinogenicity was found in rats and mice administered amlodipine 0.5, 1.25, and 2.5 mg/kg/day in their diet for 2 years. In addition, the highest dose administered in this test was close to the maximum tolerating dose in mice (a dose close to the maximum recommended clinical dose of 10 mg on a mg/m2 basis in mice, and twice the maximum recommended clinical dose in rats*).
* Based on patient weight of 50 kg
(2) Atorvastatin: Atorvastatin was not carcinogenic in rat experiments using a dose 63 times the highest human dose (80 mg/day) based on body weight converted to mg per kg, that is, 8-16 times higher dose based on AUC0-24. The results of a two-year mouse test in which a dose 250 times higher than the highest dose used in humans was administered based on body weight converted to mg per kg showed that in the group using the highest dose, the incidence of hepatocellular adenoma increased in males and hepatocellular carcinoma increased in females. Whole body exposure was 6-11 times higher than the standard AUC0-24. All other chemically similar drugs in this class induced tumors in mice and rats at repeated doses of 12 to 125 times the highest recommended clinical dose based on body weight converted to mg per kg.
2) Mutability
(1) Amlodipine: In mutation tests, this drug did not affect genes or chromosome levels.
(2) Atorvastatin: In four in vitro tests and one in vivo test, this drug showed no mutagenic potential regardless of whether it had metabolic activity. Atorvastatin was negative in the Ames test using Salmonella typhimurium and Escherichia coli and the in vitro HGPRT forward mutation assay using Chinese hamster lung cells. Atorvastatin did not significantly increase chromosomal abnormalities in the in vitro Chinese hamster lung cell test, and was negative in the in vivo mouse micronucleus test.
3) Abnormal reproductive capacity
(1) Amlodipine: In rats treated with up to 10 mg/kg/day dose of amlodipine (8 times the highest clinically recommended dose of 10 mg* based on mg/m2) (males were treated for 64 days and females for 14 days before mating), no effect on fertility was observed. * Based on patient weight of 50 kg
(2) Atorvastatin: There was no negative effect on fertility or fertility in male rats administered up to 175 mg/kg/day of atorvastatin or female rats administered up to 225 mg/kg/day. This dose was 100-140 times the highest recommended dose for human use, converted to mg per kg. In a reproductive toxicity test on male rats, when administered at 100 mg/kg/day for 11 weeks, sperm count, sperm motility, and sperm abnormalities increased. When atorvastatin was administered to dogs at doses of 10 mg/kg, 40 mg/kg, and 120 mg/kg for 2 years, there was no negative effect on sperm or semen parameters or histopathology of reproductive organs.
4) Central nervous system toxicity
Atorvastatin: It causes optic nerve degeneration (Waller degeneration of retinal geniculate fibers) in a dose-dependent manner in dogs administered this class of chemically similar drugs (approximately 30 times the maximum human dose).
(1) Cerebral hemorrhage was observed in a female dog administered at 120 mg/kg/day (about 16 times the maximum human dose) for 3 months. Cerebral hemorrhage and optic nerve vacuolization were observed after 11 weeks in female dogs administered at an increased dose up to 280 mg/kg/day.
(2) A single tonic convulsion was observed in male dogs (2 dogs: 10 mg/kg/day, 120 mg/kg/day) in a 2-year test.
(3) Central nervous system vascular damage (perivascular hemorrhage, edema, and mononuclear cell infiltration in the perivascular space) is also observed in dogs administered other drugs in this class.

11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Store in an airtight container at 15~30℃ (room temperature)

6. Packaging unit
30 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 13items

No.Product NameDetailsDate of ChangeDownload
13Atodipin Tab.Precautions for use2026.03.03PDFAtodipine Tablet_Change in precautions for use (draft).pdf
12Atodipin Tab.Precautions for use2025.02.11PDF0381_200807985_Change order for precautions for use of atodipine tablets (draft).pdf
11Atodipin Tab.Precautions for use2024.08.30PDFAtodipine tablet_Precautions for use.pdf
10Atodipin Tab.Precautions for use2018.11.12PDFAmlodipine besylate + atorvastatin calcium combination tablet revised unification adjustment plan.pdf
9Atodipin Tab.Precautions for use2018.09.14PDF0465_200807985_Precautions for use (Atodipine tablet).pdf
8Atodipin Tab.Atodipine tablets (precautions for use)2018.06.14PDFAtodipine Tablet.pdf
7Atodipin Tab.Atodipine tablets (precautions for use)2017.09.21HWPAmlodipine besylate atorvastatin calcium complex tablet container
6Atodipin Tab.Atodipine tablets (precautions for use)2015.04.29HWPAmlodipine besylate_atorvastatin calcium_complex tablet_box
5Atodipin Tab.Atodipine tablets (precautions for use)2014.04.10HWPAtorvastatin calcium-amlodipine besylate complex (oral)
4Atodipin Tab.Atodipine tablets (precautions for use)2013.05.06HWPChange order for permission information_Atodipine tablet (correction).hwp
3Atodipin Tab.Atodipine tablets (efficacy, dosage and dosage)2013.01.30HWPAtodipine tablet_change in permission details.hwp
2Atodipin Tab.Atodipine tablets (efficacy, dosage, usage, precautions...2012.12.31HWPAtodipine tablet_Permission change order.hwp
1Atodipin Tab.Atodipine tablets (precautions for use)2009.12.07HWPAtodipine tablets (precautions for use) (2009.12.07).hwp